Ayala Pharmaceuticals Inc. (AYLA)

Business: Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers.

IPO Date: 08-May-2020

Pres, CEO & Director: Dr. Roni Mamluk M.D., Ph.D.

CFO, Sec. & Treasurer: Mr. Yossi Maimon CPA, M.B.A., CPA, MBA

Listing: NASDAQ: AYLA

Country: Israel

Headquarters: Rehovot,

Website: https://www.ayalapharma.com

Market cap: $15.67 Mln

Revenue (TTM): $2.99 Mln

Earnings (TTM): $-40.71 Mln

Cash: $27.05 Mln

Total Debt: $0.47 Mln

Insider's Holding: 31.29%

Liquidity: Low

52 Week range: $0.96 - 14.95

Shares outstanding: 14,085,300